Analysis of Dynamic Efficacy Endpoints of the Nix-TB Trial.

Journal:

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Volume: 76, Issue: 11

Published:

June 8, 2023

PMID:

36804834

Authors:

Belén P Solans BP, Marjorie Z Imperial MZ, Morounfolu Olugbosi M, Rada M Savic RM

Access Paper

DOI: 10.1093/cid/ciad051

PMID: 36804834

Abstract:

Safer, better, and shorter treatments for multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) are an urgent global health need. The phase 3 clinical trial Nix-TB (NCT02333799) tested a 6-month treatment of MDR and XDR-TB consisting of high-dose linezolid, bedaquiline, and pretomanid (BPaL). In this study, we investigate the relationship between the pharmacokinetic characteristics of the drugs, patient characteristics and efficacy endpoints from Nix-TB.

Courtesy of the U.S. National Library of Medicine